Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4

Sponsor Class

OTHER 11INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 2Breast 2Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Chronic-Phase 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Advanced Breast Cancer 2Philadelphia Chromosome 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Indications Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Dasatinib × Clear all
NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Novartis

Phase 1 Completed
326 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00306202 2021-02-26

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Bristol-Myers Squibb

Phase 1 Completed
63 enrolled 55 charts
Other hematologic neoplasm

Leukemia, Recurrence

NCT00371345 2011-04-26

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Bristol-Myers Squibb

Phase 2 Completed
92 enrolled 27 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT00371254 2011-03-15

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Bristol-Myers Squibb

Phase 2 Completed
55 enrolled 28 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡